Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
OTU domain-containing protein 6B is a cysteine-type deubiquitinase, part of the OTU protease family, using a conserved catalytic triad of cysteine, histidine, and aspartate. It removes ubiquitin from protein substrates, regulating their degradation, participating in cell cycle control (in B cells), protein synthesis, growth, and proteasome function. Loss-of-function mutations in humans are linked to developmental disorders with intellectual disability, seizures, and distinct limb anomalies[1][2][3][4].
Drugs hypothetically targeting OTUD6B would likely act as inhibitors or modulators of its deubiquitinating activity, affecting protein degradation and cell cycle pathways (speculative, as no approved drugs are known[2][4])
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on OTU domain-containing protein 6B (OTUD6B).